EN
登录

阿斯利康与Immunai达成8500万美元的合作协议,推动炎症性肠病领域的人工智能驱动研究

AstraZeneca Partners with Immunai in $85 Million Deal to Advance AI-Driven Research in Inflammatory Bowel Disease

GeneOnline 等信源发布 2025-10-16 00:48

可切换为仅中文


by Mark Chiang

马克·蒋

Share To

分享到

AstraZeneca has entered into a new collaboration with Immunai, an artificial intelligence-focused biotechnology company, to advance research in inflammatory bowel disease (IBD). The partnership is valued at $85 million and builds on the companies’ existing relationship. AstraZeneca and Immunai aim to leverage AI-driven insights to identify novel therapeutic targets and accelerate drug development for IBD, a chronic condition affecting millions worldwide..

阿斯利康与专注于人工智能的生物技术公司Immunai达成了一项新的合作,以推进炎症性肠病(IBD)的研究。该合作伙伴关系价值8500万美元,并建立在两家公司现有关系的基础上。阿斯利康和Immunai旨在利用人工智能驱动的洞察,识别新的治疗靶点并加速IBD药物的开发,这是一种影响全球数百万人的慢性疾病。

The agreement highlights AstraZeneca’s continued investment in innovative technologies to address complex diseases. Immunai specializes in applying machine learning and computational biology to analyze immune system data, which will be central to this collaboration. This latest deal underscores the growing trend of pharmaceutical companies partnering with AI firms to enhance precision medicine approaches..

该协议突显了阿斯利康持续投资于创新技术以应对复杂疾病的承诺。Immunai 专注于应用机器学习和计算生物学来分析免疫系统数据,这将成为此次合作的核心。这一最新交易进一步表明了制药公司与人工智能企业合作以提升精准医疗方法的日益增长趋势。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源:GO-AI-ne1

For any suggestion and feedback, please contact us.

如果有任何建议和反馈,请联系我们。

Date: October 16, 2025

日期:2025年10月16日

Related posts:

相关文章:

New MRI Technique Developed at UC Berkeley Maps Blood Flow Patterns in Brain’s Venous System

加州大学伯克利分校开发的新核磁共振技术绘制大脑静脉系统的血流模式

Retail Pharmacy Webinar on June 20, 2025, to Address PBM Regulations and Industry Trends

2025年6月20日零售药房网络研讨会将探讨PBM法规及行业趋势

Iterum Therapeutics Launches Orlynvah as First Oral Penem Antibiotic for UTIs in Over 25 Years

Iterum Therapeutics 推出 Orlynvah,成为25年来首个用于治疗尿路感染的口服青霉烯类抗生素。

Oral Weight Loss Treatments Gain Attention as Alternative to Injections in Obesity Care

口服减肥治疗在肥胖症护理中作为注射替代品受到关注

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作:

[email protected]

电子邮件地址

Author

作者

Mark Chiang

蒋志邦

Related Post

相关内容

News Flash

新闻快讯

IIoT Adoption Accelerates Post-Pandemic to Support Sustainability and Economic Growth

后疫情时代,工业物联网采用加速,以支持可持续发展和经济增长。

2025-10-16

2025年10月16日